U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07184840) titled 'Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder' on Sept. 08.
Brief Summary: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG). The objectives of this study are to assess the efficacy and safety of eculizumab for treatment of patients with neuromyelitis optica spectrum disorders during acute phase who are anti-aquaporin-4 (AQP4) antibody-positive. Eculizumab, a humanized monoclonal antibody, inhibits the terminal complement protein C5 and prevents its cleavage int...